Form 4: Unicycive Therapeutics Director Gaurav Aggarwal Reports Acquisition and Disposal of Securities
SEC Form 4 Filing
Director Gaurav Aggarwal reports transactions involving Unicycive Therapeutics common stock and Series A-2 Prime Preferred Stock.
Summary
- On October 9, 2024, Gaurav Aggarwal, a director of Unicycive Therapeutics, reported acquiring 5,500,000 shares of common stock through the conversion of Series A-2 Prime Preferred Stock.
- Aggarwal also reported the disposal of 2,695 shares of Series A-2 Prime Preferred Stock.
- Following these transactions, Aggarwal indirectly owns 9,970,152 shares of common stock through Vivo Opportunity Fund Holdings L.P.
- He also indirectly owns 3,885.21 shares of Series A-2 Prime Preferred Stock through Vivo Opportunity Fund Holdings L.P.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's securities.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| March 14, 2024 | Shares of Series A-2 Prime Preferred Stock were issued |
| October 9, 2024 | Date of transaction: acquisition of common stock and disposal of Series A-2 Prime Preferred Stock |
| October 10, 2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.